Sumitomo Pharma disputes Gotham City Research report, says claims “clearly inconsistent” with facts

PUBT · 2d ago
Sumitomo Pharma disputes Gotham City Research report, says claims “clearly inconsistent” with facts
  • Sumitomo Pharma rebutted an Aug. 3 Gotham City Research report, calling key claims inconsistent with facts and warning of potential legal action.
  • FY ended March 31, 2026 profit included a JPY 49 billion gain on selling part of its Asia business; described as properly recognized.
  • Denied allegations that higher accounts receivable signaled channel stuffing or fictitious revenue; cited factoring differences and gross-vs-net presentation under IFRS.
  • Explained JPY 164.5 billion dividends from Swiss unit: JPY 116.2 billion offset investment carrying value, JPY 48.3 billion booked as dividend income under Japanese GAAP.
  • Stated the consolidated accounts were unaffected by the intra-group transactions; KPMG AZSA issued an unqualified audit opinion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.